Leukotriene modifiers

There are two types of agents that modify leukotriene response: inhibitors of LT synthesis that block lipo-oxygenase, and LTreceptor antagonists. The drugs zafirlukast and

target="_blank">montelukast belong to the latter group and are used more clinically. Zileuton is an inhibitor of leukotriene synthesis
In theory, these LTmodifying agents could have a major role in the treatment of asthma. Howevertheory and practice are not identical; many asthmatics appear not to have anybenefit from LT modifiers, which now are prescribed mainly for mild asthma orasthma with profound exercise-induced symptoms.


A leukotriene modifier has a combination of effects on both synthesis and leukotriene receptors.


Leukotriene modifiers are treatment of first choice in asthma.


Leukotriene modifiers are NOT used for the treatment of COPD.